Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ABEO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 -3.335M
March 31, 2026 -2.222M
December 31, 2025 3.614M
September 30, 2025 5.163M
June 30, 2025 10.50M
March 31, 2025 6.768M
December 31, 2024 5.314M
September 30, 2024 -0.299M
June 30, 2024 73.68M
March 31, 2024 25.44M
December 31, 2023 7.617M
September 30, 2023 22.98M
June 30, 2023 6.618M
March 31, 2023 -0.004M
December 31, 2022 42.77M
September 30, 2022 4.189M
June 30, 2022 -3.782M
March 31, 2022 0.00
December 31, 2021 16.33M
September 30, 2021 0.173M
June 30, 2021 2.479M
March 31, 2021 5.878M
December 31, 2020 0.003M
September 30, 2020 0.00
June 30, 2020 1.933M
Date Value
March 31, 2020 0.00
December 31, 2019 96.53M
September 30, 2019 4.34M
June 30, 2019 13.01M
March 31, 2019 0.028M
December 31, 2018
September 30, 2018 3.079M
June 30, 2018 0.57M
March 31, 2018 1.829M
December 31, 2017 87.26M
September 30, 2017 5.06M
June 30, 2017 0.084M
March 31, 2017 0.001M
December 31, 2016 41.37M
September 30, 2016 1.019M
June 30, 2016 0.15M
March 31, 2016 0.00
December 31, 2015 0.00
September 30, 2015 15.41M
June 30, 2015 20.64M
March 31, 2015 -0.40M
December 31, 2014 12.46M
September 30, 2014 0.25M
June 30, 2014 0.00
March 31, 2014 0.00

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Corcept Therapeutics, Inc. -2.037M
Forum Markets, Inc. -31.57M
ACADIA Pharmaceuticals, Inc. 10.49M
Alnylam Pharmaceuticals, Inc. 36.24M
Anika Therapeutics, Inc. -0.701M